[68Ga]Ga-Sa-DABI-4 PET Imaging of Stimulator of Interferon Gene Expression in Cancer Patients

NCT06419361 · tracked via the Priya Life Science China tracker

Sponsor

First Affiliated Hospital of Chongqing Medical University

Phase

Phase EARLY_PHASE1

Started

2024-05-30

Last updated

2025-06-04

Condition(s) studied

Stimulator of Interferon GeneCancerPositron Emission Tomography

Investigational drug(s) / intervention(s)

[68Ga]Ga-Sa-DABI-4

[68Ga]Ga-Sa-DABI-4: Each subject receives a single intravenous injection of \[68Ga\]Ga-Sa-DABI-4.

Study summary

Stimulator of interferon gene (STING) protein plays a vital role in the immune surveillance of tumor microenvironment. Monitoring STING expression in tumors benefits the relevant STING therapy. This study will investigate the safety, biodistribution and potential usefulness of a novel 68Ga-labeled agonist (\[68Ga\]Ga-Sa-DABI-4) for noninvasive positron emission tomography (PET) imaging of STING expression in the tumor microenvironment.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Accepted

Inclusion Criteria: 1. At least 18 years of age. 2. Signed informed consent. 3. Patients with suspected or newly diagnosed or previously malignant disease. Exclusion Criteria: 1. Patients with non-malignant disease. 2. Patients with pregnancy. 3. The inability or unwillingness of the research participant, parent or legal representative to provide written informed consent. 4. Known or expected hypersensitivity to \[68Ga\]Ga-Sa-DABI-4 or any of its components. 5. Any serious medical condition or extenuating circumstance which the investigator feels may interfere with the procedures or evaluations of the study.

Primary outcome measure(s)

Diagnostic efficacy — 15 days
The sensitivity, specificity, and accuracy of \[68Ga\]Ga-Sa-DABI-4 PET

Trial sites (1)

Facility	City	Region	Status
The First Affiliated Hospital of Chongqing Medical University	Chongqing	Chongqing Municipality	Recruiting

More First Affiliated Hospital of Chongqing Medical University trials in China

Mecobalamin Combined With Anti-VEGF Intravitreal Injection for Retinal Vein Occlusion Treatment Recruiting

Sertraline Combined With Multi-Strain Probiotics for Adolescent Depression Recruiting

Ivarmacitinib Combined With Camrelizumab and Apatinib for Unresectable Advanced Hepatocellular Carcinoma With Acquired Resistance to Immune Checkpoint Therapy: A Single-Arm Exploratory Clinical Study Starting soon

Metabolomics Predictors for Metabolic Disease Remission After Metabolic Syndrome Surgery. Active, not recruiting

An Integrated Multi-omics Study on the Molecular Mechanisms of Ureteral Stricture Starting soon

Other trials for the same condition

A Phase II Clinical Study Evaluating the Effectiveness of Injectable NC527-X in Intraoperative Imaging for Patients With Solid Tumors Recruiting

Immunotherapy Treating GI Cancer Starting soon

Safety and Tolerability of AI-Designed Pan-Cancer Neoantigen mRNA Vaccine (PAN-NeoVax) in Advanced Solid Tumors Recruiting

68Ga-HSA PET/CT Imaging for Protein-losing Enteropathy Starting soon

68Ga-NYM096 PET/CT in Various Kinds of Cancer Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06419361 on ClinicalTrials.gov ↗ ← All trials in China